Download PDF
Thromb Haemost 2014; 111(02): 373-374
DOI: 10.1160/TH13-05-0394
Letters to the Editor
Schattauer GmbH

Clopidogrel results in favourable changes in nitric oxide metabolism in patients undergoing percutaneous coronary intervention

Shantu Bundhoo
1   Cardiovascular Biology and Metabolism, The Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, Wales, UK
,
Ewelina Sagan
1   Cardiovascular Biology and Metabolism, The Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, Wales, UK
,
Philip E. James
1   Cardiovascular Biology and Metabolism, The Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, Wales, UK
,
Richard A. Anderson
1   Cardiovascular Biology and Metabolism, The Institute of Molecular and Experimental Medicine, School of Medicine, Cardiff University, Wales Heart Research Institute, Heath Park, Cardiff, Wales, UK
› Author Affiliations
Further Information

Publication History

Received: 16 May 2013

Accepted after major revision: 12 September 2013

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Mehta SR, Yusuf S, Peters RJ. et al. Effects of pre-treatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527-533.
    CrossrefPubMedGoogle Scholar
  • 2 Warnholtz A, Ostad MA, Velich N. et al. A single loading dose of clopidogrel causes dose-dependent improvement of endothelial dysfunction in patients with stable coronary artery disease: results of a double-blind, randomized study. Atherosclerosis 2008; 196: 689-695.
    CrossrefPubMedGoogle Scholar
  • 3 Rudez G, Duckers HJ, Simoons ML. Clopidogrel and endothelial injury after percutaneous coronary interventions: beyond the antiplatelet effects. J Am Coll Cardiol 2010; 56: 1032-1033.
    CrossrefPubMedGoogle Scholar
  • 4 Rhodes P, Leone AM, Francis PL. et al. The L-argi-nine:nitric oxide pathway is the major source of plasma nitrite in fasted humans. Biochem Biophys Res Commun 1995; 209: 590-596.
    CrossrefPubMedGoogle Scholar
  • 5 Kleinbongard P, Dejam A, Lauer T. et al. Plasma nitrite reflects constitutive nitric oxide synthase activity in mammals. Free Radic Biol Med 2003; 35: 790-796.
    CrossrefPubMedGoogle Scholar
  • 6 Pinder AG, Rogers SC, Khalatbari A. et al. The measurement of nitric oxide and its metabolites in biological samples by ozone-based chemilumines-cence. Methods Mol Biol 2009; 476: 10-27.
    CrossrefPubMedGoogle Scholar
  • 7 Cao G, Prior RL. Measurement of oxygen radical absorbance capacity in biological samples. Methods Enzymol 1999; 299: 50-62.
    CrossrefPubMedGoogle Scholar
  • 8 Ingram TE, Pinder AG, Bailey DM. et al. Low-dose sodium nitrite vasodilates hypoxic human pulmonary vasculature by a means that is not dependent on a simultaneous elevation in plasma nitrite. Am J Physiol 2010; 298: H331-339.
    PubMedGoogle Scholar
  • 9 Lundberg JO, Weitzberg E. NO generation from nitrite and its role in vascular control. Arterioscler Thromb Vasc Biol 2005; 25: 915-922.
    CrossrefPubMedGoogle Scholar
  • 10 Ingram TE, Bleasdale RA, Templeton C. et al. Low-dose sodium nitrite provides targeted relief of myocardial ischaemia in patients with coronary artery disease. Eur Heart J. Suppl 2010 31. Abstract.
    PubMedGoogle Scholar